Evidence map›Paper›PMID 30068240›Full record

ReviewTechnology in cancer research & treatment2018

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies.

Stephanie K Schaub, Pehr E Hartvigson, Michael I Lock, Morten Høyer, Thomas B Brunner, Higinia R Cardenes, Laura A Dawson, Edward Y Kim, Nina A Mayr, Simon S Lo and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Stephanie K Schaub1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Pehr E Hartvigson1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Michael I Lock2 Department of Radiation Oncology, University of Western Ontario, London, Canada.
Morten Høyer3 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark.
Thomas B Brunner4 Klinik für Strahlentherapie, Universitätsklinikum Magdeburg, Magdeburg, Germany.
Higinia R Cardenes5 Department of Radiation Oncology, Stich Radiation Center, NY, USA.
Laura A Dawson6 Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Edward Y Kim1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Nina A Mayr1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Simon S Lo1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Smith Apisarnthanarax1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
University of Washington · USAarhus University Hospital · DKKlinikum Magdeburg · DEPrincess Margaret Cancer Centre · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose-response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions.

Indexed as

Carcinoma, HepatocellularDose-Response Relationship, RadiationHumansLiverLiver NeoplasmsRadiosurgeryTreatment OutcomeHCChepatocellular carcinomaproton therapySABRSBRTstereotactic ablative radiation therapystereotactic body radiation therapy

Identifiers

PMID30068240
PMCPMC6071169
OpenAlexW2885700523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.